Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergan, Ironwood Seek To Divide And Conquer IBS With New Linzess Formulations

Executive Summary

Allergan and Ironwood Pharmaceuticals are beefing up the blockbuster potential of their IBS drug Linzess with two new formulations that target different disease populations showing promising Phase II data. Further Phase IIb and III trials are now in the offing.

You may also be interested in...

Ironwood Puts It Bluntly: Denner Lacks Case To Join Board, Wouldn’t Provide Missing Insight

Citing concerns that Linzess might not hit the blockbuster threshold by 2020, as predicted by Ironwood, one analyst lowers the firm’s stock rating on the same day the company clarifies that it does not want activist investor Alex Denner to join its board.

ESMO: Sanofi/Regeneron’s Latecomer Anti-PD-1 Libtayo Looking Likely In NSCLC

Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.

Deal Watch: Bausch Health Takes Option To Allegro Dry AMD Candidate

Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts